Good news for kids hoping for jabs in arms (which used to sound like an oxymoron before this spring): Moderna has announced promising results for its trial in adolescent-aged children. In around 4,000 adolescents, the vaccine proved to be 94.1% effective in preventing disease. No cases in the vaccinated group were found two weeks after the second shot, while 4 cases were found in the unvaccinated control group.
On Tuesday, May 25, Moderna showed in a clinical trial that its mRNA vaccine is safe and effective in people ages 12 to 17. The company will apply for FDA emergency use authorization in June. This follows the semi-recent authorization of the Pfizer-Biontech vaccine for the same age group, which happened at the end of March.
While children tend to have less severe complications from COVID-19 on the whole, serious illness is still quite possible. And even though rates across the country are falling due to more widespread vaccination, it’s still important that kids get vaccinated as herd immunity is not quite in our grasp yet.
The availability of another vaccine may help more people in this age group get protected; however, the rest of the world has nowhere near the access to vaccines that U.S. citizens over age 12 do right now. In April, health policy experts estimated that the United States might have an excess of up to 300,000 extra vaccines.
That being said, adolescents should still get vaccinated if it is available to them. This problem isn’t the fault of citizens wanting to get protection; it’s about the failures of governments and systems to provide vaccine equity.
More vaccine reporting
- Sources and updates, November 20Sources and updates for the week of November 20 include mortality trends, bivalent boosters, perceptions of COVID-19 trends, and more.
- Sources and updates, November 13Sources and updates for the week of November 13 include booster shot uptake by state, masks in schools, Paxlovid for Long COVID, and more.
- Sources and updates, November 6Sources and updates for the week of November 6 include Omicron bivalent boosters, a Long COVID clinical trial, an RSV vaccine, and more.
- Sources and updates, October 30Sources and updates for the week of October 30 include booster shot demographics, mortality data by occupation, Paxlovid prescriptions, and more.
- Sources and updates, October 23Sources and updates for the week of October 23 include flu vaccination disparities, genomic surveillance from travelers, hospital finances, and more.